UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                  FORM 10-QSB/A

                                 AMENDMENT NO. 1

[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF
      THE SECURITIES ACT OF 1934

      For the quarterly period ended                  November 30, 2002
                                                      -----------------

      Commission File Number                          0-12305
                                                      -------

                             REPRO-MED SYSTEMS, INC.
                             -----------------------
             (Exact name of registrant as specified in its charter)


New York                                              13-3044880
--------                                              ----------
(State or other jurisdiction of                       (IRS Employer
incorporation or organization)                        Identification No.)


24 Carpenter Road, Chester, NY                        10918
------------------------------                        -----
(Address of principal executive offices)              (Zip Code)


Registrant's telephone number, including area code    (845) 469-2042
                                                      --------------

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act during the
past 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the
past 90 days.

Yes ( X )   No (   )

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

            Class                      Outstanding at Nov 30 2002
            -----                      --------------------------

Common stock, $.01 par value               23,504,000 shares

<PAGE>
                             Repro-Med Systems, Inc.
                                Table of Contents

Part I                                                                      PAGE

Item 1.

      Financial Statements
      Balance Sheet (Unaudited) - November 30, 2002 ...........................3

      Statements of Operations (Unaudited) - for the three-months and
      nine months ending November 30, 2002 and November 30, 2001 ..............4

      Statements of Cash Flow (Unaudited) - for the nine months
      ending November 30, 2002 and 2001 .......................................5

      Notes to Unaudited Financial Statements .................................6

Item 2.

      Management's Discussion and Analysis of
      Financial Condition and Results of Operations. ..........................7

PART II

Item 1.

      Legal Proceedings ......................................................10

Item 2.

      Changes in Securities ..................................................10

Item 3.

      Defaults Upon Senior Securities ........................................10

Item 4.

      Submission of Matters to a Vote of Security Holders ....................10

Item 5.

      Other Information ......................................................10

Item 6.

      Exhibits and Reports on Form 8-K .......................................11

                                         2
<PAGE>

                             REPRO-MED SYSTEMS, INC.
                                  BALANCE SHEET
                                    UNAUDITED
ASSETS                                                         November 30, 2002
CURRENT ASSETS

    Cash & Cash Equivalents ....................................    $    24,303
    Accounts Receivable, net ...................................        182,405
    Inventory ..................................................        530,238
    Prepaid Expenses & Other Receivables .......................         35,067
                                                                    -----------
TOTAL CURRENT ASSETS ...........................................        772,551
                                                                    -----------
EQUIPMENT & OTHER ASSETS
    Total Equipment ............................................      1,199,772
    Less - Accumulated Depreciation ............................       (765,676)
                                                                    -----------
    Net Book Value of Equipment ................................        434,095
    Deposits ...................................................         52,000
    Other Assets ...............................................         45,867
TOTAL EQUIPMENT & OTHER ASSETS .................................        531,962
                                                                    -----------
TOTAL ASSETS ...................................................    $ 1,304,513
                                                                    ===========
LIABILITIES & STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
    Accounts Payable ...........................................    $   263,760
    Demand loan from President .................................         84,000
    Accrued Expenses ...........................................         84,013
    Bank Line of Credit Payable ................................        200,000
    Current Portion of Leases Payable ..........................         25,346
    Current Portion Capital Gain ...............................         22,481
                                                                    -----------
    Total Current Liabilities ..................................        679,600
                                                                    -----------
OTHER LIABILITIES
     Long-Term Portion of Leases Payable .......................         51,450
     Deferred Capital Gain Income ..............................        342,835
                                                                    -----------
TOTAL LIABILITIES ..............................................      1,073,885
                                                                    -----------
STOCKHOLDERS' EQUITY
    Preferred Stock, 8% Cumulative $.01
    Par Value Authorized 2,000,000 Issued &
    Outstanding 10,000 Shares (liquidation value $100,000) .....            100
    Common Stock, $.01 Par Value,
    Authorized 50,000,000 Shares, Issued &
    Outstanding 23,504,000(Includes 2,275,000
    in Treasury Shares) Respectively ...........................        235,040
    Additional Paid-in Capital .................................      2,211,631
    Accumulated Deficit ........................................     (2,074,143)
    Treasury Stock at Cost .....................................       (142,000)
                                                                    -----------
TOTAL STOCKHOLDERS' EQUITY .....................................        230,629
                                                                    -----------
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY .......................    $ 1,304,513
                                                                    ===========
            See Accompanying Notes to Unaudited Financial Statements
                                        3
<PAGE>
                             REPRO-MED SYSTEMS, INC
                            STATEMENTS OF OPERATIONS
                                    UNAUDITED


                              FOR THE 3 MONTHS ENDED    FOR THE 9 MONTHS ENDED
                              ----------------------    ----------------------
                                Nov 30,     Nov 30,       Nov 30,     Nov 30,
                                 2002        2001          2002         2001
                                 ----        ----          ----         ----
SALES

Net Sales of Products ........$ 381,547   $ 426,393   $ 1,268,628   $ 1,301,956

COST AND EXPENSES

  Cost of Goods Sold .........  260,148     323,571       883,753       953,740
  Selling, General &
    Administrative Expenses ..  128,324     155,313       406,175       485,119
  Research and Development ...    5,482      11,660        16,273        34,611
  Equity Based Compensation ..        0      10,250             0        30,750
  Depreciation and
    Amortization .............   20,160      21,387        59,757        63,164
                                -------     -------     ---------     ---------
TOTAL COST AND EXPENSES ......  414,114     522,181     1,365,958     1,567,384
                                -------     -------     ---------     ---------


(LOSS) FROM OPERATIONS .......  (32,567)    (95,788)      (97,330)     (265,428)

Non-Operating Income (Expense)
  Interest (Expense) .........   (5,158)     (5,400)      (17,820)      (13,465)
  Interest & Other Income ....    8,310         400        12,402         6,122
                                -------     -------     ---------     ---------
                                 (3,152)     (5,000)       (5,417)       (7,343)
                                -------     -------     ---------     ---------

(LOSS) BEFORE INCOME TAXES ...  (29,415)   (100,788)     (102,748)     (272,770)

    Provision for Income Taxes        0        (161)            0          (572)

NET (LOSS) AFTER TAXES .......  (29,415)   (100,949)     (102,748)     (273,342)
                                -------     -------     ---------     ---------

Preferred Dividends ..........    2,000           0         6,000         8,000

NET (LOSS) AVAILABLE TO
COMMON SHAREHOLDERS...........  (31,415)   (100,949)     (108,748)     (281,342)
                                =======    ========      ========      ========

(LOSS) PER COMMON SHARE

  Primary ....................  ($ 0.00)    ($ 0.00)    ($   0.00)    ($   0.01)
  Fully Diluted ..............  ($ 0.00)    ($ 0.00)    ($   0.00)    ($   0.01)

            See Accompanying Notes to Unaudited Financial Statements

                                         4
<PAGE>
                             REPRO-MED SYSTEMS, INC
                            STATEMENTS OF CASH FLOWS
                            FOR THE NINE MONTHS ENDED
                                    UNAUDITED

                                                         November      November
                                                         30, 2002      30, 2001
                                                         --------      --------
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss) .........................................    ($102,748)    ($273,342)
Adjustments to reconcile net (loss) to cash
 (used) in operating activities:
  Equity Based Compensation ........................            0        30,750
  Depreciation and Amortization ....................       59,757        63,164
  Deferred Gross Profit - Building Lease ...........      (16,861)      (16,861)
  Accounts Receivable ..............................       13,896        56,707
  Inventory ........................................       70,397       (63,152)
  Prepaid Expenses and Other Receivables ...........      (27,260)       19,751
  Other Assets .....................................            0          (422)
  Demand Loan to President .........................       15,000             0
  Accounts Payable .................................       74,649        67,296
  Leases Payable ...................................           52        43,332
  Other Liabilities ................................      (60,779)       25,840
                                                          -------        ------

NET CASH PROVIDED IN (USED BY) OPERATIONS ..........       26,103       (46,937)
                                                          -------        ------

CASH FLOWS USED BY INVESTING ACTIVITIES
  Capital Expenditures .............................      (23,470)      (73,388)
                                                          -------        ------
 NET CASH USED BY INVESTING ACTIVITIES .............      (23,470)      (73,388)
                                                          -------        ------

CASH FLOW PROVIDED BY FINANCING ACTIVITIES:
  Proceeds from Line of Credit .....................            0       130,000
  Preferred Stock Dividend .........................       (4,000)       (8,000)
                                                          -------        ------

CASH FLOW PROVIDED BY FINANCING ACTIVITIES: ........       (4,000)      122,000
                                                          -------        ------

NET INCREASE (IN CASH ..............................       (1,367)        1,675
  CASH, beginning of period ........................       25,670        35,466
                                                          -------        ------
  CASH, end of period ..............................    $  24,303     $  37,141
                                                        =========     =========

SUPPLEMENTAL DISCLOSURES
CASH PAYMENTS FOR
  Interest .........................................        3,741        20,252
  Income Taxes .....................................            0           572

            See Accompanying Notes to Unaudited Financial Statements

                                         5
<PAGE>

Repro-Med Systems, Inc.
Notes to the Financial Statements

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in
accordance with generally accepted accounting principles for interim financial
statements and with instructions to Form 10-QSB. Accordingly, they do not
include all of the information and disclosures required for annual financial
statements. These financial statements should be read in conjunction with the
consolidated financial statements and related footnotes for the year ended
February 28,2002 included in the Form 10-KSB for the year then ended.

As shown in the accompanying interim financial statements, the Company incurred
a net loss of $102,748 during the nine-months ended November 30,2002. The
Company intends to raise additional capital or financing, to improve their
liquidity. These factors create substantial doubt as to the Company's ability to
continue as a going concern. These financial statements do not include any
adjustments to the financial statements that might be necessary should the
Company be unable to continue as a going concern.

In the opinion of the Company's management, all adjustments (consisting of
normal recurring accruals) necessary to present fairly the Company's financial
position as of November 30,2002, and the results of operations for the
three-month and nine month periods ended November 30,2002 and 2001 and cash
flows for the periods ended November 30,2002 and 2001 have been included.

The results of operations for the three-month and nine-month periods ended
November 30,2002, are not necessarily indicative of the results to be expected
for the full year. For further information, refer to the financial statements
and footnotes thereto included in the Company's Form 10-KSB as filed with the
Securities and Exchange Commission for the year ended February 28,2002.

Reclassification - certain reclassifications have been made to prior year
amounts to conform to current year presentation.

Debt

As of November 30,2002, we have an outstanding balance of $200,000 on our bank
line of credit. The line agreement officially ended on June 30,2001 but was
verbally renewed by the bank through February 2003.

New Accounting Developments

In June 2002, the Financial Accounting Standards Board issued SFAS No. 146 on
"Accounting for Costs Associated with Exit or Disposal Activities". The

                                       6
<PAGE>

Company is reviewing the requirements and implications of adopting such
standards by December 31, 2002. This Statement addresses financial and reporting
for costs associated with exit or disposal activities and nullifies Emerging
Issues Task Force (EITF) Issue No. 94-3, "Liability Recognition for Certain
Employee Termination Benefits and Other Costs to Exit an Activity (including
Certain Costs Incurred in a Restructuring)." The Company currently does not
believe adopting such standards will have a material effect on the presentation
of the financial statements.

Part I Item 2.

Management's Discussion and Analysis of Financial Condition and Results of
Operations

This Quarterly Report on Form 10-QSB contains certain "forward-looking"
statements (as such term is defined in the Private Securities Litigation Reform
Act of 1995) and information relating to us that are based on the beliefs of the
management, as well as assumptions made by and information currently available.
Our actual results may vary materially from the forward-looking statements made
in this report due to important factors such as, recent operating losses,
uncertainties associated with future operating results, unpredictability related
to Food and Drug Administration regulations, introduction of competitive
products, limited liquidity, reimbursement related risks, government regulation
of the home health care industry, success of the research and development
effort, market acceptance of FREEDOM60, availability of sufficient capital to
continue operations and dependence on key personnel. When used in this report,
the words "estimate," "project," "believe," "anticipate," "intend," "expect" and
similar expressions are intended to identify forward-looking statements. Such
statements reflect current views with respect to future events based on
currently available information and are subject to risks and uncertainties that
could cause actual results to differ materially from those contemplated in such
forward-looking statements. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. These
statements involve risks and uncertainties with respect to the ability to raise
capital to develop and market new products, acceptance in the market place of
new and existing products, ability to penetrate new markets, our success in
enforcing and obtaining patents, obtaining required Government approvals and
attracting and maintaining key personnel that could cause the actual results to
differ materially. Repro-Med does not undertake any obligation to release
publicly any revision to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.

Three months ended November 30, 2002 vs. 2001

Sales of the Fredom60 Syringe infusion system increased quarter over quarter
ended November 30, 2002 by 36% due to increased sales in the home care market.
Res-Q-Vac sales decreased slightly by 6% due to a general world-wide

                                       7
<PAGE>

economic slowdown during the past year. Approximately 60% of Res-Q-Vac sales are
exported overseas to other countries. Net sales decreased 11% overall from
$426,393 (2001) to $381,547 (2002) for the quarter due to the loss in sales of
approximately $53,000 from a major OEM customer and reduced sales for a low
margin product line that has been phased out over the last year.

Gross profit increased to 31.8% of net sales in 2002 from 24.1% in 2001
primarily resulting from cost containment reductions.

Selling, general and administrative expense decreased 17% from 2001 to 2002 as a
result of the reduction of sales and administrative personnel, and decreased
marketing and show expenses.

Research and development expenses decreased 53% quarter over quarter due to the
fact that we enlisted outside engineering help in the second quarter 2001 but
not in the second quarter 2002.

There was no material changes in depreciation and amortization expense during
this period.


Nine Months Ended November 30, 2002 vs. 2001

Sales of our core products increased for the nine months ended November 30, 2002
vs. the nine-months ended November 30,2001, with our Freedom60 sales increasing
by 28% and Res-Q-Vac sales increasing by 14%. Net sales decreased slightly by 3%
overall from $1,301,956 (2001) to $1,268,628 (2002) for the quarter due in large
part to the loss in sales of approximately $201,318 from a major OEM customer
for the nine-months ended November 30,2002 and the elimination of a low margin
product line that has been phased out over the last year.

Gross profit increased to 30% of net sales in 2002 from 27% in 2001 primarily
resulting from cost containment reductions and reductions in material costs.

Selling, general and administrative expense continued to decrease and was down
16% from 2001 to 2002 as a result of the reduction of sales and administrative
personnel, and decreased marketing and show expenses.

Research and development expenses decreased 53% due to the fact that we enlisted
outside engineering help during the nine months ended November 30, 2001 but not
during the nine-months ended November 30,2002.

                                         8
<PAGE>

Liquidity and Capital Resources

During June 2000, we negotiated a $200,000 line of credit with M&T Bank that is
guaranteed by the President and one of the directors. The line of credit was
intended for material purchases for new orders and tooling. As of August 31,
2002, $200,000 has been advanced on the line of credit. Although the line
expired on June 30,2001, the bank verbally renewed the line through February
2003.

We are attempting to achieve and maintain positive cash flow by continuing to
increase sales for the FREEDOM60 and RES-Q-VAC, decreasing material costs and by
pursuing capital investment through debt or equity. The Company is working with
outside distributors to increase market share in the European markets for the
RES-Q-VAC, and to introduce the FREEDOM60 into the European market. Currently,
our distributor for the FREEDOM60 in Italy is marketing the product and has
received an initial order. We are in the process of validating new lower-cost
and more efficient vendors for our raw materials, which will assist us in
continuing to improve our margins on our current products. The Company has
sufficient capital for our ongoing needs based on anticipated sales growth in
the next six months and continuing to maintain careful control of expenses. The
funds available on November 30, 2002 are expected to meet cash requirements as
planned under current operating conditions at least for the next 12 months.

We have signed a reciprocal sales agreement with Trademark Medical at the end of
July for sales of Res-Q-Vac into their dental markets and we have combined their
Plak Vac dental hygiene device with the Res-Q-Vac system to provide specialty
dental hygiene to compromised patients within the home. The combined system is
low-cost and management anticipates sales from this venture. Trademark Medical
is also promoting a back-up dental version of Res-Q-Vac for sales into dental
offices along with Broadreach Medical Resources (see Below). During the past
quarter Trademark has begun marketing the Res-Q-Vac and has placed some limited
orders as interest is developed.

We attended the Medica Trade Show in Dusseldorf Germany at the end of November,
2002, and met with several new potential distributors for Freedom60 and
Res-Q-Vac. Two of these contacts are evaluating our products and we expect to
receive decision by the end of our fiscal year. As a result of our efforts at
Medica, we have received a number of orders from distributors, and expect
additional orders in the near future.

At the Medica trade show, we finalized and signed an agreement with Ferno Norden
for exclusive distribution of Res-Q-Vac within the Scandinavian countries
including Norway, Denmark Iceland, Sweden, Finland, Estonia, Latvia, and

                                       9
<PAGE>

Lithuania. And non-exclusive for Germany, Poland, and Russia. Ferno Norden had
been marketing Res-Q-Vac for several years as a non-exclusive distributor, and
we expect that our new relationship will produce improved sales within the
region. Certain minimums will be required, and with bulk shipping we anticipate
lower costs of the Res-Q-Vac landed in those countries which will further assist
in market penetration.

On September 23rd, 2002,. we signed a sales representation agreement with
Broadreach Medical Resources (BMR), and sales and marketing company to represent
Freedom60 and Res-Q-Vac in the domestic market. BMR is organizing to enter the
hospital, home care, long term care and dental markets. We have created a dental
version of Res-Q-Vac which is being made available to dentist and dental
surgeons to provide an emergency back-up to their wall suction systems which
will enable them to continue a procedure in the event of a failure. Both
Trademark Medical and BRM are jointly marketing our new Res-Q-Vac dental kit.
There are more than 200,000 dental offices in the United States and preliminary
promotions indicated strong interest. However, there can be no assurance that
significant sales will be derived from this effort. BMR has also indicated
interest in investing in our Company and further discussions are anticipated.

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

The Company is neither a party to any material litigation, nor to the knowledge
of the officers and directors of the Company, is there any material litigation
threatened against the Company.

Item 2.  Changes in Securities and Use of Proceeds

None

Item 3.  Defaults Upon Senior Securities

None

Item 4.  Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of security holders of the Company during
the quarter ended November 30, 2002.

Item 5.  Other Information

None
                                       10
<PAGE>

Item 6.  Exhibits and Reports on Form 8-K

         a) Exhibits:

         Exhibit  Description
         -------  -----------

         99.1     Certification Pursuant to Section 906 of the Sarbanes-Oxley
                  Act of 2002

         b) Reports on Form 8-K:

         None


SIGNATURES


Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange
Act of 1934 the Registrant has duly caused this report to be signed on its
behalf by the undersigned; thereunto duly authorized.

REPRO-MED SYSTEMS, INC.


/s/ Andrew I. Sealfon                           January 17, 2003

Andrew I. Sealfon, President, Treasurer,
Chairman of the Board, Director,
Chief Executive Officer and Chief Financial Officer


                                       11
<PAGE>
                                   CERTIFICATION

I, Andrew Sealfon, certify that:

1. I have reviewed this quarterly report on Form 10-QSB/A of Repro-Med Systems,
Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstance under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows, of the
registrant as of, and for the periods presented in this quarterly report;

4. The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

      a) Designed such disclosure controls and procedures to ensure that
      material information relating to the registrant, including its
      consolidated subsidiaries, is made known to us by others within those
      entities particularly during the period this quarterly report is being
      prepared;

      b) Evaluated the effectiveness of the registrant's disclosure controls and
      procedures as of a date within 90 days prior to the filing date of this
      quarterly report (the "Evaluation Date"); and

      c) Presented in this quarterly report our conclusions about the
      effectiveness of the disclosure controls and procedures based on our
      evaluation as of the Evaluation Date;

5. The registrant's other certifying officer and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
the registrant's board of directors (or persons performing the equivalent
functions):

      a) All significant deficiencies in the design or operation of internal
      controls which would adversely effect the registrant's ability to record,
      process, summarize and report financial data and have identified for the
      registrant's auditors any material weaknesses in internal controls; and

      b) Any fraud, whether or not material; that involves management or other
      employees who have a significant role in the registrant's internal
      controls; and

                                       12
<PAGE>


6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date:  January 17, 2003

                                       13